Regeneron Pharmaceuticals | REGN - Betriebsaufwand

Aktienkurs
781.60
Täglich Wechseln
21.74 2.86%
Monatlich
3.54%
Jährlich
4.94%
Q1 Prognose
736.91




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Agenus USD -274.14M 80.46M 2025-09
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Astellas Pharma JPY 436.66B 16.75B 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 67.66M 3.6M 2024-09
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.86B 115M 2025-09
Novartis USD 9.77B 401M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12